This site is intended for Healthcare professionals only.

Natco launches Hepatitis C drug in India at Rs 17,500


Natco launches Hepatitis C drug in India at Rs 17,500

Hyderabad: Natco Pharma said it has launched a fixed-dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus, in India.

The product is a generic fixed-dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg tablets, used for the treatment of patients with chronic Hepatitis C virus (HCV) infection, it said in a filing to BSE.

Natco has launched Hepcinat Plus at a maximum retail price of Rs 17,500 for a bottle of 28 tablets.



Source: PTI
0 comment(s) on Natco launches Hepatitis C drug in India at Rs 17,500

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted